MANUFACTURING

World - Class biologics manufacturing facility capabilities

To support the commercialisation of the Group's proprietary products and its partners', Uni-Bio Science Group's subsidiaries own and operate biologics manufacturing facilities in Beijing and Shenzhen which strictly adhere to the conditions and standards of the international Good Manufacturing Practices (GMPs).

The Group has invested over HKD200M in equipping its manufacturing facilities with the latest equipment, including multiple bioreactors, from leading international companies.

At its certified cGMP (China Good Manufacturing Practice) manufacturing plants in Shenzhen and Beijing, Uni-Bio Science produces and packages innovative products to be delivered to patients across China.

Uni-Bio Science continues to invest significantly in its manufacturing capabilities to ensure that all plants comply with global standards, ensuring stringent product quality control and manufacturing capacity.

Uni-Bio Science's biologics manufacturing facilities :

Beijing GeneTech

-

High speed tablet and capsule production lines

-

50L and 500L bioreactors

-

12,500m2 total floor space capable of producing both chemical and biologic drugs, compliant to latest GMP standards

-

Dedicated R&D and new formulation development centres

Shenzen Watsin

-

Liquid ophthalmic and dermatological preparations in spray and drops

-

Two 50L bioreactors

-

8,100m2 total floor space producing two biologic class I EGF drugs, compliant to latest GMP standards